ArticleNPJ science of food2026
CD13 is a bona-fide marker of bovine pre-adipocytes with potential in cultivated fat applications.
Article in NPJ science of food, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite its significant potential, cultivated fat manufacture remains a relatively inefficient process, as it primarily uses source preparations of animal-derived mesenchymal stem/stromal cells (MSC) that are poorly defined and highly heterogenous in nature, containing only relatively minor fractions of bona-fide adipocyte progenitors. The aim of this study was to use RNA-sequencing of clonal MSC populations from cattle to identify cell surface marker(s) of bona-fide pre-adipocytes to be used for efficient enrichment of MSCs, with a view to future cultivated fat applications. Adipose-derived MSC populations (n = 5 animals) were grown clonally from single cells and subsequently tested for adipogenic capacity. Adipogenic (A) and non-adipogenic (N) clones (n = 10/group) thus identified were bulk RNA-sequenced. A total of 35 cluster of differentiation (CD) genes were identified among differentially expressed transcripts, of which CD13, CD141, CD36, CD55 and CD34 were selected for further testing using flow cytometry in bovine MSCs. All antigens except CD13 were detected at negligible levels. FACS was then used to sort MSCs (n = 4 animals) into CD13+ and CD13- fractions. Sorted CD13+ cells were larger and flatter, grew significantly slower, and expressed substantially higher levels of adipogenic regulators (PPARG and CEBPA) compared to CD13- cells. Moreover, on average, adipogenic efficiency was 10.3-fold higher in CD13+ than CD13- cells, as demonstrated by BODIPY staining and confirmed by differential expression of mature adipocyte markers (FABP4, ADIPOQ, LEP), while expression of alternative lineage markers (chondrogenic and osteogenic) and ability to differentiate into bone and cartilage were both similar for CD13+ and CD13- cells. In summary, we identified CD13 as a bona-fide marker of pre-adipocytes in bovine and demonstrated the potential of using CD13-based cell selection for enriching MSC populations for cultivated fat purposes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.